Click to enlarge
| RAF inhibitors induce dimer formation between KSR and RAF, and activate KSR by CRAF. (A) GDC0879 but not PLX4720 induces BRAF/CRAF dimers. Cells overexpressing myc-CRAF and BRAF were treated with drug for 1 h and CRAF immunoprecipitates were immunoblotted for BRAF and CRAF (epitope tagged with myc). (B) GDC0879 but not PLX4720 enhances KSR/BRAF complexes. KSR immunoprecipitates were prepared from cells overexpressing FLAG-KSR and BRAF after treatment with the indicated drug for 1 h and immunoblotted using antibodies to BRAF. (C) Both GDC0879 and PLX4720 induce KSR/CRAF complexes.KSR immunoprecipitates were prepared from cells overexpressing FLAG-KSR and myc-CRAF after treatment with the indicated drug for 1 h and immunoblotted for CRAF using myc antibodies. (D and E) Requirement of KSR for drug-induced ERK activation. Lysates fromwild-type and KSR deficient fibroblasts, transfected with RASV12, were treated with the indicated doses of either GDC-0879 (D) or PLX4720 (E) for 1 h. Lysates were immunoblotted for phospho-ERK1 and 2, ERK2, and RASV12. (F) KSR and CRAF cooperate to activate MEK. Cells expressing the indicated constructs were treated with a 50 uM PLX4720 for 2 h before cell lysates were prepared and analyzed for pMEK by immunoblotting. CRAF(TM) refers to the T421M gatekeeper mutant that cannot bind to the drug(4). (G) KSR in vitro kinase reactions. Cells were cotransfected with WT or ATP binding deficient KSR and CRAF and immunoprecipitates prepared after cells were treated with an activating dose of PLX (10 uM) for 1 h. KSR immunoprecipitates were prepared, pretreated with 50 uM PLX4720 to inhibit coprecipitating RAF activity, and then tested for kinase activity using purified MEK. MEK phosphorylation was detected using a pMEK specific antibody. |
|
Rating |
|
| Source |
Proc Natl Acad Sci USA , 2011, 108, 6067-6072. PLX-4720 purchased from Selleck |
| Method |
Western blotting |
| Cell Lines |
Cells overexpressing myc-CRAF and BRAF |
| Concentrations |
10/50 µM |
| Incubation Time |
1/2 h |
| Results |
GDC0879 but not PLX4720 induced BRAF/CRAF dimer formation (Fig. A). However, both drugs induced complexes between KSR1 and CRAF and enhanced interactions between KSR1 and BRAF (Fig. B and C), which suggested that KSR1/RAF complexes induced by the drug might explain the effects ofthe type I BRAF specific inhibitors. As reported previously, treatment of wild-type cells with either drug strongly induced ERK activation at low to intermediate doses but inhibited ERK activation at higher doses (Fig. D and E). Similar results were obtained with cells expressing constitutively active RAS (Fig. D and E) or after serum treatment. Strikingly, in KSR deficient cells, ERK activation was significantly attenuated after PLX4720 or GDC0879 treatment (Fig. D and E), which demonstrates that the ability of PLX4720 and GDC0879 to activate ERK requires the presence of KSR1. We found that, when KSR1 was overexpressed withCRAF, MEK activation was induced by PLX4720 or GDC0879 treatment (Fig. F). this result suggested that induction of the CRAF/KSR1 complex might be important in the activation of MEK. In vitro kinase activity toward MEK was detected but only after drug treatment (Fig. G), which suggests KSR1/CRAF complex formation kinase activity toward MEK. |
Click to enlarge
| A, ANOVA of IC50 values of the dual PI3K/mTOR inhibitor NVP-BEZ235 in 23 melanoma cell lines showing no significant difference in sensitivity to this compound in B-Raf mutant and Braf wild-type cells. B, decreases in pAkt and pP70S6K in a dose and time-dependent fashion in 2 melanoma cell lines treated with NVP-BEZ235. pP70S6K levels are undetectable at all concentrations and time points studied, whereas levels of pAkt start rising again after 4 hours of drug exposure in a dose-dependent fashion. C, clonogenic assays in 2 melanoma cell lines (YUVON and YUSIK) treated with NVP-BEZ235 at different concentrations. NVPBEZ235 was effective in inhibiting colony formation at low nanomolar concentrations. |
|
Rating |
|
| Source |
Clin Cancer Res, 2010, 16, 6029-6039. BEZ235 (NVP-BEZ235) purchased from Selleck |
| Method |
Synergism studies, Immunoblot assays, Clonogenic assays |
| Cell Lines |
Melanoma cell |
| Concentrations |
0.1-100 μM |
| Incubation Time |
1/24 h |
| Results |
One of the proposed mechanisms of resistance to PI3KIs is mutation in the Ras-Raf pathway, which are found in more than half of melanomas. By ANOVA, no association was found between the IC50 values of NVP-BEZ235 and the presence or absence of B-Raf mutations (Fig. A). The targets of NVP-BEZ235, pAkt and pP70S6K, were both decreased with exposure to the drug in a time- and dose-dependent fashion, as shown in Figure B for YUVON and YUSIK cell lines. Clonogenicity was studied in YUVON and YUSIK cells with exposure to the dual PI3K/mTOR inhibitor. As shown in Figure C, NVP-BEZ235 effectively inhibits clonogenicity at low nanomolar concentrations. |
Click to enlarge
| Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) mM AEA. In Panel (E–F–G) washed platelets were preincubated with 1 mM SR1 (E), 1 Mm MK2206 (F) or 20 mM LY294002 (G), and then stimulated for 1min with 1.0 mM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 mM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods. |
|
Rating |
|
| Source |
J Cell Biochem, 2010, 112, 924–932. MK-2206 2HCl purchased from Selleck |
| Method |
Confocal microscopy |
| Cell Lines |
platelets |
| Concentrations |
1μM |
| Incubation Time |
|
| Results |
Upon treatment with increasing concentrations of AEA from 0.1 to 10 mM (Fig. B–D) platelets were fully fluorescently marked as compared to control (Fig. A) and the increase in DAF 2 fluorescence intensity appears to be dose-dependent. In agreement with data shown in Figure 4, SR1(Fig. E) and MK2206 (Fig. F) abolished fluorescence intensity induced by AEA, while LY294002 (Fig. 5G) was less potent. |
Click to enlarge
| Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope. |
|
Rating |
|
| Source |
Int J Proteomics, 2011, 2011, Article ID 215496. Afatinib (BIBW2992) purchased from Selleck |
| Method |
Nikon inverted-phase microscope |
| Cell Lines |
lung tumor cell lines |
| Concentrations |
0.1/1 µM |
| Incubation Time |
two weeks |
| Results |
Reduction of cell colony size formation was observed by the treatment with the irreversible HER1/2 inhibitor BIBW-2992 in H1975 and H1650 cells as seen when these cells were grown in an anchorage-dependent manner. |
Click to enlarge
| (a) Western blots examine the effects of WZ4002 alone or a combination of WZ4002 and ABT-263 in H1975 parental or SR cells in suspension. Cells were grown for 48 h and then treated with the indicated pharmacological agent(s) for another 24 h. The cleaved/total poly (ADP-ribose) polymerase-1 (PARP-1) ratio determined for each cell line using Image J software is also represented. The values are the means of three independent experiments. (b) Quantification of apoptotic cells assessed by PARP-1 cleavage from each cell line. |
|
Rating |
|
| Source |
Lab Invest, 2011, 92(3), 371-383. WZ4002 purchased from Selleck |
| Method |
Western blot |
| Cell Lines |
H1975 parental or SR cells |
| Concentrations |
0-1 μM |
| Incubation Time |
24 h |
| Results |
WZ4002 substantially reduced the phosphorylation levels of EGFR in H1975 SR cells, as well as parental cells in almost the same way (Figure 4a). However, the sensitivity of H1975 SR cells to WZ4002-induced apoptosis was considerably lower than parental cells |
Click to enlarge
| ERK activation is increased in Il6ra2/2 mice compared with WT mice. A, Total and phosphorylated (p) Stat3 and ERK were assessed in small punch biopsy wounds collected after 30 min (Stat3) or 1 d (ERK) by Western blotting. Densitometry results for the blots are provided to the right. pp , 0.05. B, Total and p-ERKs were assessed in small wounds generated in WTand Il6ra2/2 mice treated topically with vehicle (DMSO) or with the MEK inhibitor U0126.Wounds were harvested after 1 d, and western blotting was performed on lysates. C, Wound contraction was assessed macroscopically in large wounds of WT (left panel) and Il6ra2/2 mice treated daily with vehicle (DMSO) or U0126. pp , 0.05. |
|
Rating |
|
| Source |
J. Immunol, 2010, 184, 7219-7228. U0126-EtOH purchased from Selleck |
| Method |
Western blotting |
| Cell Lines |
Il6ra-/-mice |
| Concentrations |
0.4 μg/μL |
| Incubation Time |
0-10 d |
| Results |
Stat3 phosphorylation was reduced to a similar extent in Il6-/-, Il6ra-/-, and Il6-/-/Il6ra-/-mice (Fig. A) compared with WT mice. phosphorylation of the MAPK ERK1/2 was undetectable in Il6-/-mice yet increased in Il6ra-/-relative to WT mice 1 d after wounding (Fig. A). Topical application of U0126 reduced ERK phosphorylation in wounds of both WT and Il6ra-/- mice compared with vehicle-treated controls (Fig. B). The difference in wound contraction rates was significantly delayed in Il6ra-/-mice treated with U0126 compared with vehicle control-treated mice but did not reach significance in WT mice (Fig. C). |
Click to enlarge
| A, effects of p38 inhibitor SB203580 (1, 5, and 10 M) on SRP72 protein expression was evaluated by WB using antibodies against human SRP72,SRP54, and GAPDH. A decreased intensity of SRP72 bands was noted when using the inhibitor at 5M concentration at 240 min (lane 6) and 10M at 120 and 240 min (lanes 8 and 9). B, results were analyzed and RUA illustrated, finding significant results at 5M, 240 versus 0 min, and 10M, 240 versus 0 and 120 versus 0 min, respectively, (p0.05). |
|
Rating |
|
| Source |
J Biol Chem , 2010, 285, 32824–32833. SB 203580 purchased from Selleck |
| Method |
Western blot |
| Cell Lines |
Jurkat cells |
| Concentrations |
1-10 µM |
| Incubation Time |
0-240 min |
| Results |
The effect of p38 inhibitors SB203580 on SRP72, SRP54, and GAPDH protein expression was examined by WB. SB203580 induced a concentration-dependent reduction of SRP72 expression but did not affect SRP54 and GAPDH levels(Fig. A). A quantitative analysis by densitometry scanning (RUA) verified a statistically significant reduction of SRP72 expression by SB203580 (Fig. B) |
Click to enlarge
| Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 mM), JNK inhibitor (16 mM), p38 inhibitor SB203580 (20 mM), and multikinase inhibitor sorafenib (10 mM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot. |
|
Rating |
|
| Source |
J Invest Dermatol , 2011, 131, 1886–1895. Sorafenib (Nexavar) purchased from Selleck |
| Method |
Western blot |
| Cell Lines |
human melanoma cell lines M14 and WM-115 |
| Concentrations |
10 µM |
| Incubation Time |
48 h |
| Results |
To see whether inhibition of this pathway has an impact on the expression of Plk-1 in human melanoma, we used specific inhibitors of mitogen-activated protein kinase kinase (MEK) 1/2 (PD98059), multikinase inhibitor (sorafenib), c-Jun N-terminal kinase (JNK) (JNK inhibitor II), and the p38 MAPK (SB203580). Treatment of human melanoma cell lines WM-115 and M14 with these inhibitors was accompanied with significant reduction of Plk-1 protein levels (Figure a). This phenomenon was accompanied by induction of apoptosis(Figure b). |
